Table 2 Correlation between RBM47 and immunosuppressive checkpoints in CGGA and TCGA datasets.
From: RBM47 is a novel immunotherapeutic target and prognostic biomarker in gliomas
CGGA | TCGA | ||||
|---|---|---|---|---|---|
| Â | cor | pvalue | Â | cor | pvalue |
RBM47 | NA | NA | RBM47 | NA | NA |
CTLA4 | 0.204423 | 0.000207 | CTLA4 | 0.456086 | 2.34E-37 |
HVEM | 0.609312 | 2.06E-34 | HVEM | 0.604365 | 4.04E-71 |
TIGIT | 0.178596 | 0.001224 | TIGIT | 0.235322 | 2.74E-10 |
CD200R1 | 0.411617 | 1.01E-14 | CD200R1 | 0.530851 | 2.74E-52 |
CD161 | 0.413675 | 7.24E-15 | CD161 | 0.562126 | 1.00E-59 |
PD-1 | 0.442708 | 4.96E-17 | PD-1 | 0.590697 | 3.01E-67 |
TIM-3 | 0.799709 | 1.50E-73 | TIM-3 | 0.844092 | 1.20E-191 |
